Biotech · Private company
Taris Biomedical LLC
Track this companyFree. Adds Taris Biomedical LLC to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Phase 1 · Bladder Cancer TNM Staging Primary Tumor (T) T2ClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Phase 1 · Urinary Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Nivolumab Injection [Opdivo]Phase 1 · Bladder Cancer TNM Staging Primary Tumor (T) T2ClinicalTrials.gov · fetched Nov 12, 2026
- Trospium-Releasing Intravesical System (TAR-302-5018)Phase 1 · Idiopathic Overactive Bladder With Urinary IncontinenceClinicalTrials.gov · fetched Nov 12, 2026
- Trospium-Releasing Intravesical System (TAR-302-5018)Phase 1 · Neurogenic Detrusor OveractivityClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerPHASE1 · TERMINATED · started Jan 2, 2019ClinicalTrials.gov NCT03518320 · fetched Nov 12, 2026
- Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord InjuryPHASE1 · COMPLETED · started Apr 24, 2017ClinicalTrials.gov NCT03168828 · fetched Nov 12, 2026
- Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive BladderPHASE1 · COMPLETED · started Apr 4, 2017ClinicalTrials.gov NCT03109379 · fetched Nov 12, 2026
- Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder CancerPHASE1 · COMPLETED · started May 31, 2016ClinicalTrials.gov NCT02722538 · fetched Nov 12, 2026